Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant exenatide-4 - CSPC

Next Previous
Search
Drug Profile

Recombinant exenatide-4 - CSPC

Alternative Names: rE4; rExenatide-4 - CSPC

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSPC Pharma
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 15 Feb 2019 No development reported - Phase-III for Type 2 diabetes mellitus in China (SC)
  • 08 Aug 2017 CSPC ZhongQi Pharmaceutical plans a phase III trial for Type-2 diabetes mellitus (Treatment-experienced) (NCT03239119)
  • 21 Jan 2017 CSPC ZhongQi Pharmaceutical Technology completes a phase I trial in Type-2 diabetes mellitus (In volunteers) in China (NCT03199261)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top